| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/28/2000 | CA2366877A1 Chemical compounds and their uses |
| 09/28/2000 | CA2366652A1 Treatment of pulmonary hypertension |
| 09/28/2000 | CA2366650A1 Oral low dose butyrate compositions |
| 09/28/2000 | CA2366267A1 49 human secreted proteins |
| 09/28/2000 | CA2366214A1 Dsp-2 dual-specificity map kinase phosphatase |
| 09/28/2000 | CA2365247A1 49 human secreted proteins |
| 09/28/2000 | CA2365244A1 Calanolides for inhibiting btk |
| 09/28/2000 | CA2365243A1 Human transmembrane proteins |
| 09/28/2000 | CA2365238A1 48 human secreted proteins |
| 09/28/2000 | CA2365223A1 46 human secreted proteins |
| 09/28/2000 | CA2365201A1 Organic-arsenic compounds |
| 09/28/2000 | CA2364687A1 Organ arrest, protection and preservation |
| 09/28/2000 | CA2362700A1 Tricyclic indole-2-carboxylic acid compound used as nmda receptor antagonist |
| 09/28/2000 | CA2361221A1 Novel protein which induces chondrocyte differentiation |
| 09/28/2000 | CA2359568A1 The use of certain affinity nmda antagonists as antidepressants |
| 09/27/2000 | EP1038873A2 Benzo(3,4)cyclobuta(1,2-c)pyrrole derivatives as inhibitors of serotonine reuptake |
| 09/27/2000 | EP1038872A1 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands |
| 09/27/2000 | EP1038863A2 Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof |
| 09/27/2000 | EP1038528A1 Pentosan polysulfate containing medicament and implant for treating fibrosis |
| 09/27/2000 | EP1038023A1 Agonists of metabotropic glutamate receptors and uses thereof |
| 09/27/2000 | EP1038011A2 Methods of producing anti-angiogenic proteins; endostatin, angiostatin or restin, using a pichia yeast expression system |
| 09/27/2000 | EP1037994A1 Peptide antagonists of vascular endothelial growth factor |
| 09/27/2000 | EP1037985A1 Restin and methods of use thereof |
| 09/27/2000 | EP1037984A1 Cadherin-like polypeptides, methods and compositions related thereto |
| 09/27/2000 | EP1037983A1 Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof |
| 09/27/2000 | EP1037981A1 Soluble inhibitors of vascular endothelial growth factor and use thereof |
| 09/27/2000 | EP1037970A1 Secreted proteins and polynucleotides encoding them |
| 09/27/2000 | EP1037926A1 TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 09/27/2000 | EP1037922A1 A dna molecule encoding a mutant prepro-neuropeptide y, a mutant signal peptide, and uses thereof |
| 09/27/2000 | EP1037921A1 Erythropoietin with high specific activity |
| 09/27/2000 | EP1037919A1 Proteins for cancer cell specific induction of apoptosis and method for isolation thereof |
| 09/27/2000 | EP1037908A2 Human tumor necrosis factor-r2-like proteins |
| 09/27/2000 | EP1037900A1 Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies |
| 09/27/2000 | EP1037898A1 Secreted proteins |
| 09/27/2000 | EP1037894A1 Pharmaceuticals |
| 09/27/2000 | EP1037890A1 Amino-benzothiazole derivatives |
| 09/27/2000 | EP1037889A1 Novel compounds |
| 09/27/2000 | EP1037888A1 ($i(E))-3- 1-$i(N)-BUTYL- 5- 2-(2-CARBOXYPHENYL)METHOXY- 4-CHLOROPHENYL]-1$i(H)- PYRAZOL-4-YL]-2- (5- METHOXY-2,3- DIHYDROBENZOFURAN-6-YL)METHYL]- PROP-2-ENOIC ACID MONOARGININYL SALT |
| 09/27/2000 | EP1037887A1 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability |
| 09/27/2000 | EP1037886A1 Triazine angiogenesis inhibitors |
| 09/27/2000 | EP1037883A1 NOVEL HETEROCYCLICALLY SUBSTITUTED $g(a)-HYDROXYCARBOXLIC ACID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS |
| 09/27/2000 | EP1037880A1 Retinoic acid mimetic anilides |
| 09/27/2000 | EP1037878A2 Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
| 09/27/2000 | EP1037874A1 1-(adamantyl)amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 09/27/2000 | EP1037868A2 $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS |
| 09/27/2000 | EP1037665A1 Methods and compositions for inhibiting tumor cell growth |
| 09/27/2000 | EP1037662A1 Method to enhance an immune response of nucleic acid vaccination |
| 09/27/2000 | EP1037660A1 ribB |
| 09/27/2000 | EP1037658A1 Ifnar2/ifn complex |
| 09/27/2000 | EP1037655A2 Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof |
| 09/27/2000 | EP1037654A1 ribA |
| 09/27/2000 | EP1037653A1 Compositions and methods for regulating phagocytosis and icam-1 expression |
| 09/27/2000 | EP1037651A1 Small peptides and methods for treatment of asthma and inflammation |
| 09/27/2000 | EP1037649A1 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| 09/27/2000 | EP1037646A1 Ginkgo biloba leaf extracts with a reduced 4'-o-methylpyridoxine and biflavone content |
| 09/27/2000 | EP1037645A1 Processes of making north american ginseng fractions, products containing them, and use as immunomodulators |
| 09/27/2000 | EP1037639A1 Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses |
| 09/27/2000 | EP1037638A1 Agents |
| 09/27/2000 | EP1037637A1 Use of 5ht1a receptor antagonists for preventing and/or treating temporal lobe epilepsy |
| 09/27/2000 | EP1037636A1 Inhibition of membrane-associated viral replication |
| 09/27/2000 | EP1037635A1 Compounds and methods |
| 09/27/2000 | EP1037634A1 Novel administration form comprising an acid-labile active compound |
| 09/27/2000 | EP1037630A2 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds |
| 09/27/2000 | EP1037629A2 Combination of a retinoic acid metabolism blocking agent and a tocophereol |
| 09/27/2000 | EP1037627A1 Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid and of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization |
| 09/27/2000 | EP1037626A1 Multicatalytic protease inhibitors for use as anti-tumor agents |
| 09/27/2000 | EP1037623A1 Antihyperlipidemic statin-lp(a) inhibitor combinations |
| 09/27/2000 | EP1037621A1 Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
| 09/27/2000 | EP1037619A2 Selected c 10? perfluorinated hydrocarbons for liquid ventilation and artificial blood |
| 09/27/2000 | EP1037616A2 Combination of alpha-adrenergic blockers and cgmp levels-elevating compounds effective for the treatment of impotence |
| 09/27/2000 | EP1037607A1 Novel suppository form comprising an acid-labile active compound |
| 09/27/2000 | EP1037603A1 Membrane virus host range mutations and their uses as vaccine substrates |
| 09/27/2000 | EP1005351A4 An aqueous metal bicarbonate solution and method of use |
| 09/27/2000 | EP0918792B1 Dipeptide benzamidine as a kininogenase inhibitor |
| 09/27/2000 | EP0831889A4 Use of il-13 to induce 15-lipoxygenase |
| 09/27/2000 | EP0733052B1 Bicyclene derivatives, their production and use |
| 09/27/2000 | EP0575484B1 Composition comprising pdgf and dexamethasone for promoting tissue repair and regeneration |
| 09/27/2000 | CN1268176A Improved anti-IgE antibodies and method of improving polypeptides |
| 09/27/2000 | CN1268175A Catalytic monoclonal antibodies with protease activity for the selective lysis of the protein component of plaques and aggregates related to pathological conditions |
| 09/27/2000 | CN1268138A Compounds |
| 09/27/2000 | CN1268137A Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
| 09/27/2000 | CN1268130A Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| 09/27/2000 | CN1268126A Pyrimidin-2,4,6-trion derivatives and their use as metalloprotease-inhibitors |
| 09/27/2000 | CN1268122A Branched alkoxy- substituted 2-aminopyridines as NOS inhibitors |
| 09/27/2000 | CN1268061A Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer |
| 09/27/2000 | CN1268054A Combination therapy comprising amlodipine and a statin compound |
| 09/27/2000 | CN1268052A Therapeutic combinations comprising amlodipin and atorvastatin |
| 09/27/2000 | CN1268050A Pharmaceutical composition for combination of piperidinoalkanol-decongestant |
| 09/27/2000 | CN1267517A Hernia treating medicine |
| 09/27/2000 | CN1056846C Spiro-azabicyclic compounds useful in therapy |
| 09/27/2000 | CN1056835C Novel selective aromatase inhibiting compounds |
| 09/26/2000 | US6124460 Isoquinuclidine derivatives, method of manufacturing the same and therapeutic agents for hypercholesterolemia containing these compounds |
| 09/26/2000 | US6124457 Process and intermediates for a β3 -adrenergic receptor agonist |
| 09/26/2000 | US6124456 Adenosine antagonists |
| 09/26/2000 | US6124455 Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
| 09/26/2000 | US6124347 Have inhibitory action against the formation of advanced glycation end-products and are useful as pharmaceuticals for the prevention and treatment of various adult diseases, especially diabetic complications |
| 09/26/2000 | US6124346 Estrogen agonist/antagonists treatment of atherosclerosis |
| 09/26/2000 | US6124342 Pharmaceutical compositions containing pyrylium compounds, pyrylium salts and process for manufacturing a medicament containing the aforesaid compounds |
| 09/26/2000 | US6124332 Metalloproteinase inhibitors |
| 09/26/2000 | US6124330 N-[4-(Heteroarylmethyl)phenyl]-heteroarylamines |